Document is current
Any future updates will be listed below
-
Authors
Olstad, Emilie Willoch
Nordeng, Hedvig Marie Egeland
Sandve, Geir Kjetil
Lyle, Robert
Gervin, Kristina
-
Funding
Funding for this research was provided by:
European Research Council (ERC) Starting Grant “DrugsInPregnancy” (678033, 678033, 678033, 678033, 678033)
The Research Council of Norway (NFR) “Medications during pregnancy: effects on neurodevelopmental disorders in childhood and epigenetic outcomes” (241117, 241117, 241117, 241117, 241117)
- License Information
-
More Information
Article History
Received: 5 March 2022
Accepted: 12 June 2022
First Online: 28 June 2022
Declarations
:
: The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency and approval from the Regional Committees for Medical and Health Research Ethics (REC). MoBa is currently regulated by the Norwegian Health Registry Act. All MoBa participants have given their written informed consent to participate in the cohort study. The current study has been approved by REC South East Norway (REC reference: 23136, 2014/163). All data are de-identified, and the linkage between MoBa and the different health registries was handled by NIPH along with the relevant registries.
: Not applicable.
: The authors declare that they have no competing interests.
